Judy Chang-Strepka, MD
Ophthalmology · Houston, TXNPI 1659569648
Payments from drug & device makers
Across 431 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$1K
- Bausch & Lomb Americas Inc.$768
- Bausch & Lomb, A Division Of Bausch Health US, LLC$699
- Novartis$516
- Johnson & Johnson Surgical Vision, Inc.$465
- plus $4K from 25 others
What the payments were for
- Food & beverage$8,855100%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 72 | $1,300 |
| AbbVie(2 entities) | 62 | $1,160 |
| Bausch & Lomb Americas Inc. | 38 | $768 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 38 | $699 |
| Novartis | 21 | $516 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $465 |
| Oyster Point Pharma, Inc. | 21 | $458 |
| Harrow Eye, LLC | 12 | $332 |
| Amgen(2 entities) | 14 | $327 |
| Ocular Therapeutix, Inc. | 18 | $312 |
| Sun Pharmaceutical Industries Inc. | 15 | $279 |
| Aerie Pharmaceuticals, Inc. | 11 | $247 |
| Tarsus Pharmaceuticals, Inc. | 10 | $227 |
| Carl Zeiss Meditec USA, Inc. | 6 | $206 |
| Dompe US, Inc. | 7 | $204 |
| Akorn, Inc. | 12 | $162 |
| Kala Pharmaceuticals, Inc. | 10 | $158 |
| Biotissue Holdings Inc. | 7 | $144 |
| Shire North American Group Inc | 10 | $129 |
| Sight Sciences, Inc. | 6 | $127 |
| Astellas Pharma US Inc | 5 | $114 |
| Glaukos Corporation | 5 | $109 |
| Carl Zeiss Meditec, Inc. | 2 | $106 |
| Eyevance Pharmaceuticals LLC | 5 | $94 |
| Thea Pharma Inc. | 3 | $63 |
| Akorn Operating Company LLC | 2 | $44 |
| NEW World Medical,inc. | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Merz North America, Inc. | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Rxsight Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARGOS$132
- Precision 1$125
How this compares
$8,875 in reported general payments places this provider in the 80th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 249 | $271,105 |
| LumiganBimatoprost | 327 | $155,264 |
| XiidraLifitegrast | 105 | $118,564 |
| MieboPerfluorohexyloctane/Pf | 102 | $88,775 |
| Cyclosporine | 105 | $73,510 |
| ProlensaBromfenac Sodium | 169 | $58,470 |
| Lotemax SmLoteprednol Etabonate | 187 | $46,445 |
| BesivanceBesifloxacin Hcl | 182 | $39,866 |
| CombiganBrimonidine Tartrate/Timolol | 63 | $25,265 |
| Alphagan PBrimonidine Tartrate | 76 | $25,082 |
| RocklatanNetarsudil Mesylat/Latanoprost | 37 | $21,574 |
| VyzultaLatanoprostene Bunod | 44 | $21,347 |
| TyrvayaVarenicline Tartrate | 19 | $15,596 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 69 | $10,994 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 31 | $8,422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,160 | $476,716715 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $768 | $228,687251 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Besivance, Loteprednol Etabonate | $699 | $146,674552 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $247 | $28,63949 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $458 | $15,59619 claims |
| AlconSimbrinza | $1,300 | $8,42231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Houston
- David BrownHouston$51.7M
- John MichelettiHouston$3.3M
- Michael CaplanHouston$1.4M
- Shaheen KavoussiHouston$1.3M
- Kevin JongHouston$1.2M
- Stephen SladeHouston$1.2M
- Rosa TangHouston$1.1M
- Zaina Al-MohtasebHouston$1.1M
- Fiaz ZamanHouston$1M
- Stephen PflugfelderHouston$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.